The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

"Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP" was originally created and published by ...

UK-based pharmaceutical company GSK has reported positive outcomes from two Phase III trials of depemokimab for treating chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. The ANCHOR-1 ...

The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...

For the CRSwNP indication, the BLA includes data from the ANCHOR-1 (ClinicalTrials.gov Identifier: NCT05274750) and ANCHOR-2 (ClinicalTrials.gov Identifier: NCT05281523) trials, which enrolled ...

Mepolizumab significantly improved outcomes in patients with CRSwNP who had 1 or more previous surgeries for nasal polyps.

Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire (tezepelumab-ekko) for treating chronic rhinosinusitis with nasal polyps (CRSwNP).

Kaivan Khavandi, SVP and global head, respiratory, immunology & inflammation R&D, GSK, said: “Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help ...

Type 2 inflammation, driven by IL-5, is a key factor in difficult-to-treat asthma and is present in up to 85% of CRSwNP cases. In the U.S., over 26 million people have asthma, leading to 100,000 ...

It is also present in up to 85% of people with CRSwNP, associated with more severe disease and symptoms. In the US, asthma affects over 26 million individuals, with 40% reporting at least one ...

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...